Market Cap 221.42M
Revenue (ttm) 146.07M
Net Income (ttm) -196.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -134.21%
Debt to Equity Ratio -0.45
Volume 308,400
Avg Vol 480,820
Day's Range N/A - N/A
Shares Out 22.66M
Stochastic %K 45%
Beta 0.83
Analysts Strong Sell
Price Target $15.57

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 658 0600
Address:
85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States
Biotech_Beast
Biotech_Beast Jul. 1 at 11:13 PM
$GERN I'm long this name. Glimmers of commercial growth with Q1'26 look good and although there is competition in frontline MF from $KPTI and $NVS , imetelstat is not without a chance of success. https://seekingalpha.com/article/4919177-geron-corporation-commercial-performance-could-dovetail-with-impactmf-run-up
2 · Reply
JuggernautRaider
JuggernautRaider Jun. 29 at 3:56 PM
$KPTI lol Ipsen bought Kartos and not Karyopharm? How come CEO Richard Paulson and Karyopharm’s BD team couldn’t get that deal? Uncle Rolli and I could tell you why… we are focused on fixing biotechs, not just selling them on the cheap because private companies are often more poorly run than publicly traded ones. 🏦 $SLS $CCCC and $ALLR ALL DAY over the Krazy Pharm of Newton Massachusetts 😂
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 27 at 5:22 AM
$ALLR $CCCC $KPTI $INCY hmm who will Incyte buy next? 💊 Vega Therapeutics will not sustain them for long … will it? 🤔
0 · Reply
Watson66
Watson66 Jun. 26 at 8:47 PM
$KPTI Later!
0 · Reply
Sauce27x
Sauce27x Jun. 26 at 4:23 PM
$KPTI denied again fuck
1 · Reply
celebratelife
celebratelife Jun. 25 at 9:47 PM
$KPTI options are dead. Zero speculation of success being traded on. But also no bearish trades. Just dead. Nobody's counting on this horrible CEO to be able to pull it off, even with good data. He's even fuck up the best data - look at his lousy track record: 5 years of fucking up KPTI - destroying it by over 95% as himself and the lousy Board and Mike Mano et al were paid millions. A CEO like that turning around a company? No chance. And he has no turnaround experience in his weak resume. Firing him is wha the Board should have done 4 years ago. But they don't give a shit as long as those fucking direct deposits keep coming. Just opinions based on known facts.
0 · Reply
celebratelife
celebratelife Jun. 24 at 9:08 PM
$KPTI We're stuck at fucking 60 cents down from 25 (pre-RS units) or $9 down from $375 due to this lousy CEO and Board who've gotten richer and richer at our cost while company value has been destroyed due to their lameass shit mismanagement of the company. Winners: Richard Paulson, Barry Greene and the rest of that useless irresponsible Board, short sellers, Dempsey and other receiver of the money these clowns gave away. Losers: anybody who trusted this lousy CEO, Board, their lousy General Council and lousy ex-CFO and ex-Board members who are all responsible for this mess, and all made millions. Our only option: holding these clowns accountable and liable, legally, for every penny they got: Karma is a bitch.
0 · Reply
punktdot
punktdot Jun. 24 at 2:10 PM
$KPTI double digits, can we hold it?
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 24 at 11:16 AM
$KPTI 😂
0 · Reply
celebratelife
celebratelife Jun. 23 at 9:52 PM
$KPTI 375,000 share trade at 9.20. That's 5.6m shares pre-RS. Every year Richard Paulson and the horrible irresponsible Board have further damaged the company value, while they paid themseleves fat salaries and bonuses and shorts have made a ton of money too - at our cost.
0 · Reply
Latest News on KPTI
Karyopharm Therapeutics Transcript: Study result

Jun 2, 2026, 2:00 PM EDT - 4 weeks ago

Karyopharm Therapeutics Transcript: Study result


Karyopharm Therapeutics Press release: Study result

Jun 2, 2026, 2:00 PM EDT - 4 weeks ago

Karyopharm Therapeutics Press release: Study result


Karyopharm Therapeutics Slides: Study result

Jun 2, 2026, 2:00 PM EDT - 4 weeks ago

Karyopharm Therapeutics Slides: Study result


Karyopharm Therapeutics Transcript: AGM 2026

May 21, 2026, 9:00 AM EDT - 6 weeks ago

Karyopharm Therapeutics Transcript: AGM 2026


Karyopharm Therapeutics Slides: Corporate presentation

May 17, 2026, 7:00 AM EDT - 6 weeks ago

Karyopharm Therapeutics Slides: Corporate presentation


Karyopharm reports Q1 EPS ($1.24), consensus ($1.44)

2026-05-14T12:06:55.000Z - 7 weeks ago

Karyopharm reports Q1 EPS ($1.24), consensus ($1.44)


Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M

2026-05-14T12:04:59.000Z - 7 weeks ago

Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M


Karyopharm Therapeutics Earnings Call Transcript: Q1 2026

May 14, 2026, 8:00 AM EDT - 7 weeks ago

Karyopharm Therapeutics Earnings Call Transcript: Q1 2026


Karyopharm Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 7 weeks ago

Karyopharm Therapeutics Earnings release: Q1 2026


Karyopharm Therapeutics Slides: Q1 2026

May 14, 2026, 8:00 AM EDT - 7 weeks ago

Karyopharm Therapeutics Slides: Q1 2026


Karyopharm Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 7 weeks ago

Karyopharm Therapeutics Quarterly report: Q1 2026


Karyopharm to Participate at Upcoming Investor Conferences

May 12, 2026, 7:30 AM EDT - 7 weeks ago

Karyopharm to Participate at Upcoming Investor Conferences


Karyopharm files $400M mixed securities shelf

2026-05-04T20:43:12.000Z - 2 months ago

Karyopharm files $400M mixed securities shelf


Karyopharm price target raised to $16 from $8 at Piper Sandler

2026-04-27T10:52:35.000Z - 2 months ago

Karyopharm price target raised to $16 from $8 at Piper Sandler


Karyopharm Therapeutics Slides: Corporate presentation

Apr 16, 2026, 7:00 AM EDT - 2 months ago

Karyopharm Therapeutics Slides: Corporate presentation


Karyopharm Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Proxy statement: Proxy filing


Karyopharm price target lowered to $16 from $23 at RBC Capital

2026-04-07T15:11:06.000Z - 3 months ago

Karyopharm price target lowered to $16 from $23 at RBC Capital


Karyopharm price target lowered to $8 from $12 at Piper Sandler

2026-03-30T11:31:21.000Z - 3 months ago

Karyopharm price target lowered to $8 from $12 at Piper Sandler


Karyopharm price target lowered to $15 from $21 at Baird

2026-03-25T11:26:32.000Z - 3 months ago

Karyopharm price target lowered to $15 from $21 at Baird


Karyopharm Therapeutics Transcript: Study result

Mar 24, 2026, 8:00 AM EDT - 3 months ago

Karyopharm Therapeutics Transcript: Study result


Karyopharm Therapeutics Press release: Study result

Mar 24, 2026, 8:00 AM EDT - 3 months ago

Karyopharm Therapeutics Press release: Study result


Karyopharm Therapeutics Slides: Study result

Mar 24, 2026, 8:00 AM EDT - 3 months ago

Karyopharm Therapeutics Slides: Study result


Karyopharm announces $30M private placement

2026-03-24T11:05:33.000Z - 3 months ago

Karyopharm announces $30M private placement


Karyopharm initiated with a Buy at Rodman & Renshaw

2026-03-09T20:20:12.000Z - 4 months ago

Karyopharm initiated with a Buy at Rodman & Renshaw


Karyopharm Therapeutics Transcript: EGM 2026

Feb 18, 2026, 9:00 AM EST - 4 months ago

Karyopharm Therapeutics Transcript: EGM 2026


Karyopharm Therapeutics Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:00 AM EST - 5 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q4 2025


Karyopharm Therapeutics Annual report: Q4 2025

Feb 12, 2026, 8:00 AM EST - 5 months ago

Karyopharm Therapeutics Annual report: Q4 2025


Karyopharm Therapeutics Earnings release: Q4 2025

Feb 12, 2026, 8:00 AM EST - 5 months ago

Karyopharm Therapeutics Earnings release: Q4 2025


Karyopharm Therapeutics Slides: Q4 2025

Feb 12, 2026, 8:00 AM EST - 5 months ago

Karyopharm Therapeutics Slides: Q4 2025


Karyopharm reports Q4 EPS ($5.71) vs. ($3.67) last year

2026-02-12T12:46:18.000Z - 5 months ago

Karyopharm reports Q4 EPS ($5.71) vs. ($3.67) last year


Karyopharm initiated with an Overweight at Cantor Fitzgerald

2026-02-05T10:10:10.000Z - 5 months ago

Karyopharm initiated with an Overweight at Cantor Fitzgerald


Karyopharm sees FY25 revenue $145M, consensus $147.83M

2026-01-12T12:17:22.000Z - 6 months ago

Karyopharm sees FY25 revenue $145M, consensus $147.83M


Karyopharm Therapeutics Proxy statement: Proxy Filing

Jan 9, 2026, 7:00 AM EST - 6 months ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 30, 2025, 7:00 AM EST - 6 months ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm to Participate in Baird's Biotech Discovery Series

Dec 8, 2025, 7:00 AM EST - 7 months ago

Karyopharm to Participate in Baird's Biotech Discovery Series


Karyopharm Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 8 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q3 2025


Karyopharm Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 8 months ago

Karyopharm Therapeutics Earnings release: Q3 2025


Karyopharm Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 8:00 AM EST - 8 months ago

Karyopharm Therapeutics Quarterly report: Q3 2025


Karyopharm Therapeutics Slides: Q3 2025

Nov 3, 2025, 8:00 AM EST - 8 months ago

Karyopharm Therapeutics Slides: Q3 2025


Karyopharm Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q2 2025


Karyopharm Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Karyopharm Therapeutics Quarterly report: Q2 2025


Karyopharm Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Karyopharm Therapeutics Earnings release: Q2 2025


Karyopharm Therapeutics Slides: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Karyopharm Therapeutics Slides: Q2 2025


Karyopharm Therapeutics Slides: FY 2025

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Karyopharm Therapeutics Slides: FY 2025


Karyopharm Therapeutics Slides: Corporate Presentation

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Karyopharm Therapeutics Slides: Corporate Presentation


Karyopharm Therapeutics Transcript: AGM 2025

May 28, 2025, 9:00 AM EDT - 1 year ago

Karyopharm Therapeutics Transcript: AGM 2025


Karyopharm Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q1 2025


Karyopharm Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Quarterly report: Q1 2025


Karyopharm Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Earnings release: Q1 2025


Karyopharm Therapeutics Slides: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Slides: Q1 2025


Karyopharm Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 24, 2025, 8:40 AM EST - 1 year ago

Karyopharm Announces 1-for-15 Reverse Stock Split


Karyopharm Therapeutics Earnings Call Transcript: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q4 2024


Karyopharm Therapeutics Annual report: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Annual report: Q4 2024


Karyopharm Therapeutics Earnings release: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings release: Q4 2024


Karyopharm Therapeutics Slides: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Slides: Q4 2024


Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 16, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 5, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing


Karyopharm Therapeutics Earnings Call Transcript: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q3 2024


Karyopharm Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Quarterly report: Q3 2024


Karyopharm Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings release: Q3 2024


Karyopharm Therapeutics Slides: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Slides: Q3 2024


Karyopharm Therapeutics Transcript: Study Update

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Transcript: Study Update


Karyopharm Therapeutics Press release: Study Update

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Press release: Study Update


Karyopharm Therapeutics Slides: Study Update

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Slides: Study Update


Karyopharm Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Earnings Call Transcript: Q2 2024


Karyopharm Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Quarterly report: Q2 2024


Karyopharm Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Earnings release: Q2 2024


Karyopharm Therapeutics Slides: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Karyopharm Therapeutics Slides: Q2 2024


Biotech_Beast
Biotech_Beast Jul. 1 at 11:13 PM
$GERN I'm long this name. Glimmers of commercial growth with Q1'26 look good and although there is competition in frontline MF from $KPTI and $NVS , imetelstat is not without a chance of success. https://seekingalpha.com/article/4919177-geron-corporation-commercial-performance-could-dovetail-with-impactmf-run-up
2 · Reply
JuggernautRaider
JuggernautRaider Jun. 29 at 3:56 PM
$KPTI lol Ipsen bought Kartos and not Karyopharm? How come CEO Richard Paulson and Karyopharm’s BD team couldn’t get that deal? Uncle Rolli and I could tell you why… we are focused on fixing biotechs, not just selling them on the cheap because private companies are often more poorly run than publicly traded ones. 🏦 $SLS $CCCC and $ALLR ALL DAY over the Krazy Pharm of Newton Massachusetts 😂
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 27 at 5:22 AM
$ALLR $CCCC $KPTI $INCY hmm who will Incyte buy next? 💊 Vega Therapeutics will not sustain them for long … will it? 🤔
0 · Reply
Watson66
Watson66 Jun. 26 at 8:47 PM
$KPTI Later!
0 · Reply
Sauce27x
Sauce27x Jun. 26 at 4:23 PM
$KPTI denied again fuck
1 · Reply
celebratelife
celebratelife Jun. 25 at 9:47 PM
$KPTI options are dead. Zero speculation of success being traded on. But also no bearish trades. Just dead. Nobody's counting on this horrible CEO to be able to pull it off, even with good data. He's even fuck up the best data - look at his lousy track record: 5 years of fucking up KPTI - destroying it by over 95% as himself and the lousy Board and Mike Mano et al were paid millions. A CEO like that turning around a company? No chance. And he has no turnaround experience in his weak resume. Firing him is wha the Board should have done 4 years ago. But they don't give a shit as long as those fucking direct deposits keep coming. Just opinions based on known facts.
0 · Reply
celebratelife
celebratelife Jun. 24 at 9:08 PM
$KPTI We're stuck at fucking 60 cents down from 25 (pre-RS units) or $9 down from $375 due to this lousy CEO and Board who've gotten richer and richer at our cost while company value has been destroyed due to their lameass shit mismanagement of the company. Winners: Richard Paulson, Barry Greene and the rest of that useless irresponsible Board, short sellers, Dempsey and other receiver of the money these clowns gave away. Losers: anybody who trusted this lousy CEO, Board, their lousy General Council and lousy ex-CFO and ex-Board members who are all responsible for this mess, and all made millions. Our only option: holding these clowns accountable and liable, legally, for every penny they got: Karma is a bitch.
0 · Reply
punktdot
punktdot Jun. 24 at 2:10 PM
$KPTI double digits, can we hold it?
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 24 at 11:16 AM
$KPTI 😂
0 · Reply
celebratelife
celebratelife Jun. 23 at 9:52 PM
$KPTI 375,000 share trade at 9.20. That's 5.6m shares pre-RS. Every year Richard Paulson and the horrible irresponsible Board have further damaged the company value, while they paid themseleves fat salaries and bonuses and shorts have made a ton of money too - at our cost.
0 · Reply
celebratelife
celebratelife Jun. 20 at 11:33 PM
$KPTI 80 fucking million shorted shares (pre-RS unit) betting against horrible CEO&BoD. Latest short interest: 5,348,401 (per-RS unit). This foolish, incompetent CEO and the useless, irresponsible BoD think they can turn KPTI around after destroying it. Sad for them: no cash left to cover their legal liability; they'll have to fund that themselves. They have plenty of money - for us - after years of getting our money and doing diddly squat that ever translated to value - except for the short sellers who love'em. Paulson still thinks he has 3 shots on the goal - with no cash any more since he splurged it all on that useless, unproductive, wasteful, entitled, lazy, vacation club style "culture" he's so fucking proud of - funded by us. But miracles do rarely happen so let's see. But the best of data, Paulson, Mano et al. will screw it that up too. And if it translates to money, it seems Paulson will make sure shareholders don't see any: he'd rather give it to Dempsey et al. - IMHO
1 · Reply
celebratelife
celebratelife Jun. 18 at 9:50 PM
$KPTI 2 big blocks dumped at the close. I guess someone's seeing through Paulson's three shots of the goaln delusional BS talk. He's been giving us BS talk for over 5 fucking years as he's gotten paid millions despite having destroyed KPTI with his bullshit mismanagement and playing fucking Russian Roulette with the money he was entrusted with to create value - he splurged instead.
1 · Reply
celebratelife
celebratelife Jun. 18 at 8:43 PM
$KPTI The useless Board should have fired Paulson's ass years ago. Instead it cost us a hundreds of millions in value, and the Board and Paulson got paid millions. Paulson will never be able to take Karyopharm to the next level - even with the best of data. He proves that point time and again. Resign Richard. It's almost too late. Our future now depends on one binary event but Paulson seems triple vision, and never sees money as an issue as long as he has shareholders to dilute.
0 · Reply
Doozio
Doozio Jun. 18 at 1:46 AM
$KPTI chop chop huckleberries. It was always ONTO 🐒🍌🧠⏰♾️
0 · Reply
celebratelife
celebratelife Jun. 15 at 3:43 PM
$KPTI Paulson's ignorant stupid BS answer to biotech reporter at EHA.
0 · Reply
mich1282
mich1282 Jun. 14 at 1:30 PM
$KPTI meaningful > promising
1 · Reply
celebratelife
celebratelife Jun. 13 at 10:41 PM
$KPTI With pennies left because financial discipline and sense of urgency were foreign concepts to damn Richard Party Paulson for 5 years as KPTI value was destroyed yet him and the useless Board received millions for doing jack shit that's ever translated into value - Paulson couldn't stay away from another trans-atlantic plush trip paid by us, to attend EHA in Stockholm. His presence as always adds zero value, and to the contrary put the company and it's vacation club culture into deeper financial trouble. The presentation can be done perfectly well without him but Party Paulson just can't stay away to save money which is not part of his CEO-DNA -- his miserable track record has proved that. Just ask McDreamy Dempsey : his org got a TON of our money which these clowns raised with toxic financing and then fucking gave it away! That's much they care about their mandate, and shareholders. In this interview he mentioned still having multiple shots on goal - with 3 months of cash left!!!
0 · Reply
laaarsas
laaarsas Jun. 12 at 7:27 PM
$KPTI Olaparib also competitor in basically the same setting. The business outlook for this company is not great.
1 · Reply
laaarsas
laaarsas Jun. 12 at 6:32 PM
$KPTI trying to remind myself about the XPORT endo study. So the patients are not give CPI maintainance, right? So is this actually a clinically relevant design? Wouldn't the patients receive CPI maintainance in real world? Someone care to help me?
0 · Reply
laaarsas
laaarsas Jun. 12 at 5:46 PM
$KPTI when is data expected?
1 · Reply
laaarsas
laaarsas Jun. 12 at 1:57 PM
$KPTI why is this garbage up today?
1 · Reply
Sauce27x
Sauce27x Jun. 11 at 7:12 PM
$KPTI are we finally gonna push thru 10!!!!
1 · Reply